Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways

被引:104
作者
Fukumori, T
Takenaka, Y
Oka, N
Yoshii, T
Hogan, V
Inohara, H
Kanayama, HO
Kim, HRC
Raz, A [1 ]
机构
[1] Wayne State Univ, Sch Med, Karmanos Canc Inst, Tumor Progress & Metastasis Program, Detroit, MI 48201 USA
[2] Univ Tokushima, Sch Med, Dept Urol, Tokushima 770, Japan
[3] Osaka Univ, Grad Sch Med, Dept Otolaryngol & Sensory Organ Surg, Suita, Osaka, Japan
[4] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA
关键词
D O I
10.1158/0008-5472.CAN-04-0336
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Studies of CD95 (APO-1/Fas), a member of the death receptor family, have revealed that it is involved in two primary CD95 apoptotic signaling pathways, one regulated by the large amount of active caspase-8 (type I) formed at the death-inducing signaling complex and the other by the apoptogenic activity of mitochondria (type II). To date, it is still unclear which pathway will be activated in response to an apoptotic insult. Here, we demonstrate that the antiapoptotic molecule galectin-3, which contains the four amino acid-anti-death-motif (NWGR) conserved in the BH1 domain of the Bcl-2 member proteins, is expressed only in type I cells. Transfection of galectin-3 cDNA into galectin-3 null cells (type II) resulted converting them to type I apoptotic phenotype. In addition, we show that galectin-3 is complexed with CD95 in vivo identifying galectin-3 as a novel CD95-binding partner that determines which of the CD95 apoptotic signaling pathways the cell will select.
引用
收藏
页码:3376 / 3379
页数:4
相关论文
共 14 条
  • [1] Akahani S, 1997, CANCER RES, V57, P5272
  • [2] Molecular ordering of the initial signaling events of CD95
    Algeciras-Schimnich, A
    Shen, L
    Barnhart, BC
    Murmann, AE
    Burkhardt, JK
    Peter, ME
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (01) : 207 - 220
  • [3] GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369
  • [4] The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis
    Imai, Y
    Kimura, T
    Murakami, A
    Yajima, N
    Sakamaki, K
    Yonehara, S
    [J]. NATURE, 1999, 398 (6730) : 777 - 785
  • [5] Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO
  • [6] 2-N
  • [7] Apoptosis by death factor
    Nagata, S
    [J]. CELL, 1997, 88 (03) : 355 - 365
  • [8] TRANSFORMATION-RELATED CHANGES IN THE EXPRESSION OF ENDOGENOUS CELL LECTINS
    RAZ, A
    MEROMSKY, L
    ZVIBEL, I
    LOTAN, R
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1987, 39 (03) : 353 - 360
  • [9] Two CD95 (APO-1/Fas) signaling pathways
    Scaffidi, C
    Fulda, S
    Srinivasan, A
    Friesen, C
    Li, F
    Tomaselli, KJ
    Debatin, KM
    Krammer, PH
    Peter, ME
    [J]. EMBO JOURNAL, 1998, 17 (06) : 1675 - 1687
  • [10] Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
    Scaffidi, C
    Schmitz, I
    Zha, JP
    Korsmeyer, SJ
    Krammer, PH
    Peter, ME
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (32) : 22532 - 22538